News

LUNA is an ongoing double-masked, randomized Phase 2 trial. OPTIC is an ongoing, open-label, dose-ranging first-in-human trial.

Gregg T. Kokame, MD, MMM, FASRS, is set to share data from a predefined subgroup of the sozinibercept Phase 2b wet AMD trial related to patients with polypoidal choroidal vasculopathy (PCV), measured at 24 weeks.

ARVN001 is indicated for the treatment of uveitic macular edema (UME) and certain other ophthalmic indications under development.

Key findings include reduced lesion growth, retinal tissue preservation, and improved visual function, demonstrating significant potential for the treatment option.

This year’s Barcelona meeting brought together award-winning research findings and leaders in the retina field.

The designations underscore the unmet need in Stargardt disease, a rare and serious pediatric disease for which no treatment exists.

FYB203 has been recommended by the CHMP for approval in Europe for treating adult patients with age-related neovascular macular degeneration (nAMD) and other serious retinal diseases.

The FDA comments in the CRL relate to proposed labelling language, not safety, Astellas said in a press release.

Ian C. Han, MD, shares his thoughts on the value of anecdotal evidence in our winter 2024 editorial.

Optical coherence tomography will be in all eye care services by October 2025

The biosimilar now known by the brand name OPUVIZ was previously known as the biosimilar candidate SB15.

In a recent Modern Retina case-based discussion, Ferhina S. Ali, MD, MPH, discussed how to effectively manage geographic atrophy (GA).

A case report demonstrates independent effect of GLP-1 receptor agonist.

This merger creates an innovative biotechnology company with a broader focus in the advancement of multiple disease therapies.

The annual meeting, held in Chicago, Illinois, featured new data and best practices for patient-centered care.

This announcement establishes Boehringer as the first pharmaceutical company to join the MTM Vision Consortium.

Afqlir (aflibercept) is a 2 mg vial kit and pre-filled syringe for intravitreal injection.

Srinivas R. Sadda, MD, described the advantages and disadvantages of the various imaging technologies used to evaluate GA at the AAO 2024 conference.

Neovascular macular degeneration is multifactorial, which requires future agents to target multiple pathways.

Options empower patients and providers to decrease treatment burden

Clinical associations, imaging strategies and establishing a differential diagnosis from pseudopapilledema.

PST-611 is a first in class non-viral vectorized therapy for the treatment of dry AMD/GA coding for human transferrin.

The Healthcare Private Equity team has advised Retina Consultants of America (RCA) and Webster Equity Partners in the sale of RCA to Cencora.

"The De Novo authorization established Valeda as the first device for treatment of dry AMD patients with vision loss and creates a threshold for this novel class of photobiomodulation (PBM) devices..."

This drug is the world’s first-ever CRISPR/Cas13 RNA-editing therapy for clinical use in treating neovascular age-related macular degeneration (nAMD).

Peking University researchers have developed a deep learning-based, noninvasive choroidal angiography method that enables detailed 3D visualization of choroidal vessels from OCT scans. This technique could improve diagnostics for retinal diseases like macular degeneration, offering a safer alternative to traditional methods.

A recent cohort study revealed low adoption of FDA-approved AI-based diabetic retinopathy detection, with less than 5% of diabetic patients receiving ophthalmic imaging. Researchers emphasize the need for improved awareness, cost-effectiveness, and integration to increase diabetic retinopathy screening rates.

Katherine Talcott, MD, discussed other potential therapies and their mechanisms of action being evaluated in clinical trials at the OSN New York 2024 conference.

Dr. Mammo discussed this evolution and how to choose patients who would best benefit from GA therapy.